An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Trial Profile

An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Radium 223 chloride (Primary) ; Paclitaxel
  • Indications Bone metastases; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 09 Dec 2017 Results (n=7) of safety results from the breast cancer patient subgroup, were presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 01 Sep 2017 According to a Bayer media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top